Sugi Predict

Sugi Predict / Compounds / SCHEMBL1307339

SCHEMBL1307339

SCHEMBL1307339

O=C(NCCn1cnc2cc(C(=O)N3C4CCC3CC(O)C4)ccc21)N1CCC(O)C1

nearest known ligand 0.47

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ HPGD P15428 10/20 0.47
▸ ALDH1A1 P00352 4/20 0.39
▸ MAPK1 P28482 2/20 0.39
▸ MEN1 O00255 2/20 0.39
▸ KMT2A Q03164 2/20 0.39
▸ NAMPT P43490 1/20 0.38
▸ F2 P00734 1/20 0.38
▸ VNN1 O95497 1/20 0.37
▸ TSHR P16473 1/20 0.37
▸ OXTR P30559 1/20 0.37
▸ GAA P10253 1/20 0.37
▸ NPC1 O15118 2/20 0.36
▸ USP2 O75604 1/20 0.36
▸ RAB9A P51151 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1306682 0.95 HPGD (0.44) HPGDALDH1A1MAPK1MEN1KMT2A
SCHEMBL12117301 0.90 HPGD (0.45) HPGDALDH1A1MAPK1MEN1KMT2A
SCHEMBL1308069 0.90 HPGD (0.42) HPGDALDH1A1MAPK1MEN1KMT2A
SCHEMBL12034937 0.90 HPGD (0.42) HPGDALDH1A1MAPK1MEN1KMT2A
SCHEMBL1306300 0.89 MAPK1 (0.48) HPGDALDH1A1MAPK1MEN1KMT2A
SCHEMBL1306667 0.88 HPGD (0.42) HPGDALDH1A1MAPK1MEN1KMT2A
SCHEMBL3818854 0.86 HPGD (0.46) HPGDALDH1A1MAPK1MEN1KMT2A
SCHEMBL12034908 0.82 HPGD (0.43) HPGDALDH1A1MAPK1MEN1KMT2A
SCHEMBL12053721 0.81 HPGD (0.42) HPGDALDH1A1MAPK1MEN1KMT2A
SCHEMBL3812592 0.80 HSD17B10 (0.46) HPGDALDH1A1MAPK1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110312949-A1 PHARMACEUTICAL USE OF SUBSTITUTED AMIDES HIGH POINT PHARMACEUTICALS, LLC (US) 2011-12-22 — — US disclosed
US-20110312949-A1 PHARMACEUTICAL USE OF SUBSTITUTED AMIDES HIGH POINT PHARMACEUTICALS, LLC (US) 2011-12-22 — — US disclosed
US-8053431-B2 Pharmaceutical use of substituted amides HIGH POINT PHARMACEUTICALS, LLC (US) 2011-11-08 — — US disclosed
US-8053431-B2 Pharmaceutical use of substituted amides HIGH POINT PHARMACEUTICALS, LLC (US) 2011-11-08 — — US disclosed
US-8053431-B2 Pharmaceutical use of substituted amides HIGH POINT PHARMACEUTICALS, LLC (US) 2011-11-08 — — US disclosed
US-20090118259-A1 PHARMACEUTICAL USE OF SUBSTITUTED AMIDES HIGH POINT PHARMACEUTICALS, LLC 2009-05-07 — — US disclosed
US-20090118259-A1 PHARMACEUTICAL USE OF SUBSTITUTED AMIDES HIGH POINT PHARMACEUTICALS, LLC 2009-05-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090118259-A1 PHARMACEUTICAL USE OF SUBSTITUTED AMIDES HSD11B1, CYP11B1, HSD11B2 HPGD 27/4885ALDH1A1 187/4885MAPK1 1496/4885
US-20110312949-A1 PHARMACEUTICAL USE OF SUBSTITUTED AMIDES HSD11B1, HSD3B1, HSD11B2 HPGD 28/4885ALDH1A1 206/4885MAPK1 1770/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.